HSPA9 and neoplasm: Thus, the SMR peptides, through their antagonism of mortalin, block EV release and, in the tumor cell lines we examined, allow drug resistant tumor cells to reestablish the complement attack complex and complement mediated cytotoxicity of the target tumor cells, while having no similar effect on normal growing cells.